CoChat

Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein

Open access

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

Background: Natural killer and cytotoxic CD8+ T cells are major players during antitumor immunity. They express NKG2D, an activating receptor that promotes tumor elimination through recognition of the MHC class I chain-related proteins A and B (MICA and MICB). Both molecules are overexpressed on a great variety of tumors from different tissues, making them attractive targets for immunotherapy. However, tumors shed MICA and MICB, and the soluble forms of both (sMICA and sMICB) mediate tumor-immune escape. Some reports indicate that anti-MICA antibodies (Ab) can promote the restoration of antitumor immunity through the induction of direct antitumor effects (antibody-dependent cell-mediated cytotoxicity, ADCC) and scavenging of sMICA. Therefore, we reasoned that an active induction of anti-MICA Ab with an immunogenic protein might represent a novel therapeutic and prophylactic alternative to restore antitumor immunity. Methods: We generated a highly immunogenic chimeric protein (BLS-MICA) consisting of human MICA fused to the lumazine synthase from Brucella spp (BLS) and used it to generate anti-MICA polyclonal Ab (pAb) and to investigate if these anti-MICA Ab can reinstate antitumor immunity in mice using two different mouse tumors engineered to express MICA. We also explored the underlying mechanisms of this expected therapeutic effect. Results: Immunization with BLS-MICA and administration of anti-MICA pAb elicited by BLS-MICA significantly delayed the growth of MICA-expressing mouse tumors but not of control tumors. The therapeutic effect of immunization with BLS-MICA included scavenging of sMICA and the anti-MICA Ab-mediated ADCC, promoting heightened intratumoral M1/proinflammatory macrophage and antigen-experienced CD8+ T cell recruitment. Conclusions: Immunization with the chimeric protein BLS-MICA constitutes a useful way to actively induce therapeutic anti-MICA pAb that resulted in a reprogramming of the antitumor immune response towards an antitumoral/proinflammatory phenotype. Hence, the BLS-MICA chimeric protein constitutes a novel antitumor vaccine of potential application in patients with MICA-expressing tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2019-000233

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 MICA RNA is overexpressed in the human tumors that exhibit high number of deaths compared with matched normal tissues. RNAseq data of expression of different NKG2DL (indicated at the top of each panel) in the indicated human tumors. The red horizontal line in each graph indicates the cut-off value to consider upregulated expression. Data presented were obtained from the cBioPortal for cancer genomics (http://www.cbioportal.org/). The graph corresponds to 1084 breast tumors, 594 colorectal tumors, 372 liver tumors, 566 lung adenocarcinomas, 487 lung squamous cell carcinomas and 440 stomach carcinomas. MICA, MHC class I chain-related protein A; MICB, MHC class I chain-related protein B; NKG2DL, ligand of NKG2D.
Figure 1 MICA RNA is overexpressed in the human tumors that exhibit high number of deaths compared with matched normal tissues. RNAseq data of expression of different NKG2DL (indicated at the top of each panel) in the indicated human tumors. The red horizontal line in each graph indicates the cut-off value to consider upregulated expression. Data presented were obtained from the cBioPortal for cancer genomics (http://www.cbioportal.org/). The graph corresponds to 1084 breast tumors, 594 colorectal tumors, 372 liver tumors, 566 lung adenocarcinomas, 487 lung squamous cell carcinomas and 440 stomach carcinomas. MICA, MHC class I chain-related protein A; MICB, MHC class I chain-related protein B; NKG2DL, ligand of NKG2D.CC BY-NC · PubMed Central
Figure 2 Immunization of mice with BLS-MICA generates high titers of anti-MICA pAb. (A) ELISA with plates coated with BLS-MICA and incubated with serial dilutions of an anti-MICA/B (D7, red) or an anti-BLS (BI24, blue) mAb. (B) ELISA with plates coated with BLS-MICA and incubated with serial dilutions of rabbit pAb raised against peptides spanning the α1 (#620 and #621) or the α2 (#622) domains of MICA. (C) Outline of the immunization schedule used to immunize C57BL/6 mice. After 3, 5 and 7 weeks of starting the protocol, blood samples were collected from the animals (indicated by numbers 1, 2 and 3, respectively) to analyze the presence of anti-MICA pAb. (D) ELISA with plates coated with rMICA and incubated with serial dilutions of sera from mice collected after 3 (blue), 5 (yellow) and 7 (red) weeks after starting the immunization protocol. Graphs show representative results of one immunization plan performed with five animals per group immunized with BLS alone, BLS and CFA, BLS-MICA alone or BLS-MICA and CFA. Mean±SEM is shown. Ab, antibody; BLS, Brucella lumazine synthase; BLS-MICA, BLS coupled to MICA; CFA, complete Freund’s adjuvant; mAb, monoclonal antibody; MICA, MHC class I chain-related protein A; MICB, MHC class I chain-related protein B; NRS, normal rabbit serum; pAb, polyclonal Ab.
Figure 2 Immunization of mice with BLS-MICA generates high titers of anti-MICA pAb. (A) ELISA with plates coated with BLS-MICA and incubated with serial dilutions of an anti-MICA/B (D7, red) or an anti-BLS (BI24, blue) mAb. (B) ELISA with plates coated with BLS-MICA and incubated with serial dilutions of rabbit pAb raised against peptides spanning the α1 (#620 and #621) or the α2 (#622) domains of MICA. (C) Outline of the immunization schedule used to immunize C57BL/6 mice. After 3, 5 and 7 weeks of starting the protocol, blood samples were collected from the animals (indicated by numbers 1, 2 and 3, respectively) to analyze the presence of anti-MICA pAb. (D) ELISA with plates coated with rMICA and incubated with serial dilutions of sera from mice collected after 3 (blue), 5 (yellow) and 7 (red) weeks after starting the immunization protocol. Graphs show representative results of one immunization plan performed with five animals per group immunized with BLS alone, BLS and CFA, BLS-MICA alone or BLS-MICA and CFA. Mean±SEM is shown. Ab, antibody; BLS, Brucella lumazine synthase; BLS-MICA, BLS coupled to MICA; CFA, complete Freund’s adjuvant; mAb, monoclonal antibody; MICA, MHC class I chain-related protein A; MICB, MHC class I chain-related protein B; NRS, normal rabbit serum; pAb, polyclonal Ab.CC BY-NC · PubMed Central
Figure 3 Mouse cell lines transduced with retroviral vectors encoding MICA express high amounts of this NKG2DL on their cell surface that is recognized by sera of mice immunized with BLS-MICA. (A) EL4 and MB49 cells were infected with control (empty) retroviruses (pMSCV) or with retroviruses encoding MICA*008 to generate the EL4-pMSCV, EL4-MICA*008, MB49-pMSCV and MB49-MICA*008 cell lines, and expression of MICA was assessed with the 6D4 mAb (anti-MICA/B), the anti-MICA mAb 159 227 or the anti-MICB mAb 236 511 by FC. Gray: IC mAb; black lines: anti-MICA/B, anti-MICA or anti-MICB mAb. HCT116 cells: positive control for MICA and MICB expression. (B) MB49-pMSCV, MB49-MICA*008 and HCT116 cell lines were labeled using a pool of sera of mice immunized with BLS-MICA (‘anti-MICA’, black line histogram) or with normal mouse serum (preimmune, gray histogram) and analyzed by FC. Ab, antibody; BLS, Brucella lumazine synthase; FC, flow cytometry; IC, isotype control; BLS-MICA, BLS coupled to MICA; mAb, monoclonal antibody; MICA, MHC class I chain-related protein A; MICB, MHC class I chain-related protein B; NKG2DL, ligand of NKG2D.
Figure 3 Mouse cell lines transduced with retroviral vectors encoding MICA express high amounts of this NKG2DL on their cell surface that is recognized by sera of mice immunized with BLS-MICA. (A) EL4 and MB49 cells were infected with control (empty) retroviruses (pMSCV) or with retroviruses encoding MICA*008 to generate the EL4-pMSCV, EL4-MICA*008, MB49-pMSCV and MB49-MICA*008 cell lines, and expression of MICA was assessed with the 6D4 mAb (anti-MICA/B), the anti-MICA mAb 159 227 or the anti-MICB mAb 236 511 by FC. Gray: IC mAb; black lines: anti-MICA/B, anti-MICA or anti-MICB mAb. HCT116 cells: positive control for MICA and MICB expression. (B) MB49-pMSCV, MB49-MICA*008 and HCT116 cell lines were labeled using a pool of sera of mice immunized with BLS-MICA (‘anti-MICA’, black line histogram) or with normal mouse serum (preimmune, gray histogram) and analyzed by FC. Ab, antibody; BLS, Brucella lumazine synthase; FC, flow cytometry; IC, isotype control; BLS-MICA, BLS coupled to MICA; mAb, monoclonal antibody; MICA, MHC class I chain-related protein A; MICB, MHC class I chain-related protein B; NKG2DL, ligand of NKG2D.CC BY-NC · PubMed Central
Figure 4 Immunization with BLS-MICA delays growth of tumors that express MICA. (A) Outline of the active immunization and tumor challenge schedule. Mice were immunized with BLS or BLS-MICA as indicated (four immunizations). Then, mice were rested for 3 weeks, challenged with MB49-MICA*008 tumors, and tumor growth was assessed. (B) Pie charts showing the percentage of mice immunized with BLS (left) or BLS-MICA (right) that developed palpable tumors at day 8 after challenge. (C) Tumor growth curves in mice immunized with BLS (blue) or with BLS-MICA (red). Mean±SEM is shown. Statistically significant differences between groups started at day 8 after tumor challenge. ****p<0.0001, two-way ANOVA with Sidak’s posthoc test. (D) Amounts of sMICA (expressed as MFI) detected in sera of mice immunized with BLS (blue dots) or BLS-MICA (red dots) and challenged with MB49-MICA*008 tumor cells at the time of euthanasia (15 days after tumor challenge). Each dot corresponds to one mouse (**p=0.008, unpaired two-tailed Student’s t-test. (E) Correlation analysis between the amount of sMICA and tumor volume (R Spearman=0.7706, p<0.0001). Data from mice immunized with BLS (blue) or with BLS-MICA (red) were plotted together. Data shown in the graph correspond to cumulative results from two independent experiments. n=14 mice per group (B–D) and n=28 (E). ANOVA, analysis of variance; BLS, Brucella lumazine synthase; BLS-MICA, BLS coupled to MICA; MFI, median fluorescence intensity; MICA, MHC class I chain-related protein A; MICB, MHC class I chain-related protein B; sMICA, soluble MICA.
Figure 4 Immunization with BLS-MICA delays growth of tumors that express MICA. (A) Outline of the active immunization and tumor challenge schedule. Mice were immunized with BLS or BLS-MICA as indicated (four immunizations). Then, mice were rested for 3 weeks, challenged with MB49-MICA*008 tumors, and tumor growth was assessed. (B) Pie charts showing the percentage of mice immunized with BLS (left) or BLS-MICA (right) that developed palpable tumors at day 8 after challenge. (C) Tumor growth curves in mice immunized with BLS (blue) or with BLS-MICA (red). Mean±SEM is shown. Statistically significant differences between groups started at day 8 after tumor challenge. ****p<0.0001, two-way ANOVA with Sidak’s posthoc test. (D) Amounts of sMICA (expressed as MFI) detected in sera of mice immunized with BLS (blue dots) or BLS-MICA (red dots) and challenged with MB49-MICA*008 tumor cells at the time of euthanasia (15 days after tumor challenge). Each dot corresponds to one mouse (**p=0.008, unpaired two-tailed Student’s t-test. (E) Correlation analysis between the amount of sMICA and tumor volume (R Spearman=0.7706, p<0.0001). Data from mice immunized with BLS (blue) or with BLS-MICA (red) were plotted together. Data shown in the graph correspond to cumulative results from two independent experiments. n=14 mice per group (B–D) and n=28 (E). ANOVA, analysis of variance; BLS, Brucella lumazine synthase; BLS-MICA, BLS coupled to MICA; MFI, median fluorescence intensity; MICA, MHC class I chain-related protein A; MICB, MHC class I chain-related protein B; sMICA, soluble MICA.CC BY-NC · PubMed Central
Figure 5 Anti-MICA pAb passively administered to tumor-bearing mice delay growth of tumors that express MICA associated with an increased accumulation of tumor infiltrating M1/proinflammatory macrophages and antigen-experienced CD8+ T cells. (A) Outline of the tumor challenge and passive immunization schedule. Mice were challenged with control (EL4-pMSCV or MB49-pMSCV) or MICA-expressing (EL4-MICA*008 or MB49-MICA*008) tumors at day 0. When tumors reached a palpable size, mice were passively immunized with sera from mice previously immunized with BLS (Ctrl pAb) or with BLS-MICA (anti-MICA) every 2 days, and tumor growth was assessed. (B) Pie charts showing the percentage of mice challenged with EL4-pMSCV (upper charts) or EL4-MICA*008 (lower charts) cells and immunized with Ctrl pAb (left) or anti-MICA (right) that developed tumors greater than 500 mm3 at day 11 after challenge. The tumor volume of 500 mm3 was selected because in our experience tumors of that size invariably progress. (C) Tumor growth curves of MB49-pMSCV (left) or MB49-MICA*008 (right) cells, in mice treated with Ctrl pAb or with anti-MICA pAb. **p<0.01, ****p<0.0001, two-way ANOVA with Sidak’s posthoc test. (D) Kaplan-Meier curves corresponding to mice challenged with EL4-MICA*008 cells (upper graph) or MB49-MICA*008 cells (lower graph) and treated with Ctrl pAb or with anti-MICA pAb. Differences between the two groups were significant (*p=0.0223 for EL4-MICA*008 cells and **p=0.016 for MB49-MICA*008 cells, log-rank Mantel-Cox test). Of note, it was not possible to extend the experiments up to 120 days with MB49 cells as these tumors tend to ulcerate and due to ethical reasons, mice were euthanized. (E) Pie charts showing the percentage of mice challenged with MB49-pMSCV (upper charts) or MB49-MICA*008 (lower charts) cells that underwent surgery to remove the tumor and that were then immunized with Ctrl pAb (left) or anti-MICA (right) that developed palpable tumors at day 42 after surgery (tumors of more than 60 mm3). n=4 per group (B–E). Data shown in B to E correspond to one representative experiment which was performed twice with similar results. (F–H) Mice were challenged with MB49-MICA*008 tumor cells and passively immunized with control pAb (Ctrl Ab, blue dots) or with anti-MICA pAb (anti-MICA, red dots) every 2 days starting when tumor became palpable as indicated in panel A. After 12 days, mice were euthanized, and the composition of the tumor infiltrate was analyzed by FC (outlined in online supplementary figure 2). (F) MFI of CD274, CD86 and MHC-II in F4/80+ cells (macrophages). (G) Percentage of CD44+CD8+ cells. (H) Representative histograms (numbers correspond to MFI) of CD274, CD86 and MHC-II in F4/80+ cells (macrophages) and pseudocolor plots (numbers correspond to percentages) of CD44+CD8+ cells. Each dot in F and G represents the data from one mouse. Data shown in the graphs correspond to cumulative results from two independent experiments. **p<0.01, ***p<0.001. An unpaired two-tailed Student’s t-test was used in F and G. CD274: n=9 (Ctrl Ab), n=10 (anti-MICA Ab), p=0.0007. CD86: n=8 (Ctrl Ab and anti-MICA Ab), p=0.0016. MHC-II: n=8 (Ctrl Ab and anti-MICA Ab), p=0.0032. CD44+: n=7 (Ctrl Ab), n=8 (anti-MICA Ab), p=0.0016. Ab, antibody; ANOVA, analysis of variance; BLS, Brucella lumazine synthase; BLS-MICA, BLS coupled to MICA; Ctrl Ab, control Ab; FC, flow cytometry; MFI, median fluorescence intensity; MICA, MHC class I chain-related protein A; MICB, MHC class I chain-related protein B pAb, polyclonal Ab.
Figure 5 Anti-MICA pAb passively administered to tumor-bearing mice delay growth of tumors that express MICA associated with an increased accumulation of tumor infiltrating M1/proinflammatory macrophages and antigen-experienced CD8+ T cells. (A) Outline of the tumor challenge and passive immunization schedule. Mice were challenged with control (EL4-pMSCV or MB49-pMSCV) or MICA-expressing (EL4-MICA*008 or MB49-MICA*008) tumors at day 0. When tumors reached a palpable size, mice were passively immunized with sera from mice previously immunized with BLS (Ctrl pAb) or with BLS-MICA (anti-MICA) every 2 days, and tumor growth was assessed. (B) Pie charts showing the percentage of mice challenged with EL4-pMSCV (upper charts) or EL4-MICA*008 (lower charts) cells and immunized with Ctrl pAb (left) or anti-MICA (right) that developed tumors greater than 500 mm3 at day 11 after challenge. The tumor volume of 500 mm3 was selected because in our experience tumors of that size invariably progress. (C) Tumor growth curves of MB49-pMSCV (left) or MB49-MICA*008 (right) cells, in mice treated with Ctrl pAb or with anti-MICA pAb. **p<0.01, ****p<0.0001, two-way ANOVA with Sidak’s posthoc test. (D) Kaplan-Meier curves corresponding to mice challenged with EL4-MICA*008 cells (upper graph) or MB49-MICA*008 cells (lower graph) and treated with Ctrl pAb or with anti-MICA pAb. Differences between the two groups were significant (*p=0.0223 for EL4-MICA*008 cells and **p=0.016 for MB49-MICA*008 cells, log-rank Mantel-Cox test). Of note, it was not possible to extend the experiments up to 120 days with MB49 cells as these tumors tend to ulcerate and due to ethical reasons, mice were euthanized. (E) Pie charts showing the percentage of mice challenged with MB49-pMSCV (upper charts) or MB49-MICA*008 (lower charts) cells that underwent surgery to remove the tumor and that were then immunized with Ctrl pAb (left) or anti-MICA (right) that developed palpable tumors at day 42 after surgery (tumors of more than 60 mm3). n=4 per group (B–E). Data shown in B to E correspond to one representative experiment which was performed twice with similar results. (F–H) Mice were challenged with MB49-MICA*008 tumor cells and passively immunized with control pAb (Ctrl Ab, blue dots) or with anti-MICA pAb (anti-MICA, red dots) every 2 days starting when tumor became palpable as indicated in panel A. After 12 days, mice were euthanized, and the composition of the tumor infiltrate was analyzed by FC (outlined in online supplementary figure 2). (F) MFI of CD274, CD86 and MHC-II in F4/80+ cells (macrophages). (G) Percentage of CD44+CD8+ cells. (H) Representative histograms (numbers correspond to MFI) of CD274, CD86 and MHC-II in F4/80+ cells (macrophages) and pseudocolor plots (numbers correspond to percentages) of CD44+CD8+ cells. Each dot in F and G represents the data from one mouse. Data shown in the graphs correspond to cumulative results from two independent experiments. **p<0.01, ***p<0.001. An unpaired two-tailed Student’s t-test was used in F and G. CD274: n=9 (Ctrl Ab), n=10 (anti-MICA Ab), p=0.0007. CD86: n=8 (Ctrl Ab and anti-MICA Ab), p=0.0016. MHC-II: n=8 (Ctrl Ab and anti-MICA Ab), p=0.0032. CD44+: n=7 (Ctrl Ab), n=8 (anti-MICA Ab), p=0.0016. Ab, antibody; ANOVA, analysis of variance; BLS, Brucella lumazine synthase; BLS-MICA, BLS coupled to MICA; Ctrl Ab, control Ab; FC, flow cytometry; MFI, median fluorescence intensity; MICA, MHC class I chain-related protein A; MICB, MHC class I chain-related protein B pAb, polyclonal Ab.CC BY-NC · PubMed Central
Figure 6 Anti-MICA pAb passively administered to tumor-bearing mice promote ADCC. (A) In vitro ADCC of mouse NK cells against MB49-pMSCV or MB49-MICA*008 cells preincubated with control pAb (Ctrl Ab) or anti-MICA pAb (anti-MICA) assessed at 2 E:T ratios (indicated in the x-axis). YAC-1 cells were used as positive control of NK cell-mediated cytotoxicity. (B) In vivo ADCC against MB49-pMSCV (yellow dots) or MB49-MICA*008 tumor cells (green dots) preincubated with control pAb (Ctrl Ab) or anti-MICA pAb (anti-MICA). The relative abundance of CFSE+ and eFluorDye670+ cells (each tumor cell) recovered after 72 hours of subcutaneous challenge of naive mice with tumor cells preincubated with control or anti-MICA pAb was analyzed by FC. An unpaired two-tailed Student’s t-test was used. ****p<0.0001. (C) Tumor growth of tumor cells preincubated with control or anti-MICA pAb injected in naive mice. MB49-pMSCV (blue and green dots) or MB49-MICA*008 tumor cells (yellow and red dots) were incubated in vitro with control pAb (Ctrl Ab, blue and yellow dots) or anti-MICA Ab (green and red dots), injected in naive mice and tumor growth was assessed. Each dot in B and C correspond to one mouse. n=4 per group (B, C). Data shown correspond to one representative experiment which was performed twice with similar results. ****p<0.0001, two-way ANOVA with Sidak’s posthoc test. Ab, antibody; ADCC, antibody-dependent cell-mediated cytotoxicity; ANOVA, analysis of variance; CFSE, carboxyfluorescein succinimidyl ester; Ctrl Ab, control Ab; FC, flow cytometry; MFI, median fluorescence intensity; MICA, MHC class I chain-related protein A; pAb, polyclonal Ab.
Figure 6 Anti-MICA pAb passively administered to tumor-bearing mice promote ADCC. (A) In vitro ADCC of mouse NK cells against MB49-pMSCV or MB49-MICA*008 cells preincubated with control pAb (Ctrl Ab) or anti-MICA pAb (anti-MICA) assessed at 2 E:T ratios (indicated in the x-axis). YAC-1 cells were used as positive control of NK cell-mediated cytotoxicity. (B) In vivo ADCC against MB49-pMSCV (yellow dots) or MB49-MICA*008 tumor cells (green dots) preincubated with control pAb (Ctrl Ab) or anti-MICA pAb (anti-MICA). The relative abundance of CFSE+ and eFluorDye670+ cells (each tumor cell) recovered after 72 hours of subcutaneous challenge of naive mice with tumor cells preincubated with control or anti-MICA pAb was analyzed by FC. An unpaired two-tailed Student’s t-test was used. ****p<0.0001. (C) Tumor growth of tumor cells preincubated with control or anti-MICA pAb injected in naive mice. MB49-pMSCV (blue and green dots) or MB49-MICA*008 tumor cells (yellow and red dots) were incubated in vitro with control pAb (Ctrl Ab, blue and yellow dots) or anti-MICA Ab (green and red dots), injected in naive mice and tumor growth was assessed. Each dot in B and C correspond to one mouse. n=4 per group (B, C). Data shown correspond to one representative experiment which was performed twice with similar results. ****p<0.0001, two-way ANOVA with Sidak’s posthoc test. Ab, antibody; ADCC, antibody-dependent cell-mediated cytotoxicity; ANOVA, analysis of variance; CFSE, carboxyfluorescein succinimidyl ester; Ctrl Ab, control Ab; FC, flow cytometry; MFI, median fluorescence intensity; MICA, MHC class I chain-related protein A; pAb, polyclonal Ab.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 32

Metadata

Authors
Torres, N., Regge, M. V., Secchiari, F., Friedrich, A. D., Spallanzani, R. G., Raffo Iraolagoitia, X. L., Núñez, S. Y., Sierra, J. M., Ziblat, A., Santilli, M. C., Gilio, N., Almada, E., Lauche, C., Pardo, R., Domaica, C. I., Fuertes, M. B., Madauss, K. P., Hance, K. W., Gloger, I. S., Zylberman, V., Goldbaum, F. A., & Zwirner, N. W.
Affiliations
  • Laboratorio de Fisiopatología de la Inmunidad Innata, Instituto de Biologia y Medicina Experimental, Buenos Aires, Argentina
  • Experimental Medicine and Biology Institute (AR)
  • Inmunova, Buenos Aires, Argentina
  • GlaxoSmithKline (United States) (US)
  • GlaxoSmithKline (United Kingdom) (GB)
  • Fundación Instituto Leloir (AR)
  • Universidad de Buenos Aires (AR)
Corresponding author
Zwirner, Norberto Walter
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2020-06
Volume
8
Issue
1
Pages
e000233
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3033899855
Cited by
29
References
45
Citations by year
2026: 4 · 2025: 7 · 2024: 4 · 2023: 2 · 2022: 5 · 2021: 7
FWCI
1.22
Type
journal article
Language
en
Open access
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • GlaxoSmithKline
  • Fundación Williams
  • Consejo Nacional de Investigaciones Científicas y Técnicas
  • Sapienza Università di Roma
  • Universidad de Buenos Aires (CONICET)
  • Fundación René Barón
  • Agencia Nacional de Promoción Científica y Tecnológica (CONICET)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
mica, MICB, anti-MICA antibodies, fusion protein, lumazine synthase, Brucella, antitumor immunity, tumor immune evasion, soluble MICA, antibody-dependent cellular cytotoxicity, NKG2D, CD8+ T cells, M1 macrophages, cancer vaccines, immunogenic proteins
MeSH terms
Animals, Antibodies, Monoclonal, Antibody-Dependent Cell Cytotoxicity, Urinary Bladder Neoplasms, Brucella, Female, Lymphoma, Male, Mice, Inbred C57BL, Multienzyme Complexes, Recombinant Fusion Proteins, Tumor Cells, Cultured, Histocompatibility Antigens Class I, Mice, NK Cell Lectin-Like Receptor Subfamily K

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein. https://app.cochat.ai/papers/10.1136/jitc-2019-000233
The paper
Torres, N., Regge, M. V., Secchiari, F., Friedrich, A. D., Spallanzani, R. G., Raffo Iraolagoitia, X. L., Núñez, S. Y., Sierra, J. M., Ziblat, A., Santilli, M. C., Gilio, N., Almada, E., Lauche, C., Pardo, R., Domaica, C. I., Fuertes, M. B., Madauss, K. P., Hance, K. W., Gloger, I. S., . . . Zwirner, N. W. (2020). Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2019-000233

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.